China Pharma Holdings annual stock-based compensation
2010
2011
2012
2013
2021
2022
2023
China Pharma Holdings Stock-Based Compensation Growth & History (CPHI)
China Pharma Holdings's stock-based compensation was $0 for fiscal 2023.
View full China Pharma Holdings company overviewChina Pharma Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2023 | 2023-12-31 | $0 | −$78,270 | — |
| 2022 | 2022-12-31 | $78,270 | $63,027 | +413.48% |
| 2021 | 2021-12-31 | $15,243 | — | — |
| 2013 | 2013-12-31 | $0 | −$141,721 | — |
| 2012 | 2012-12-31 | $141,721 | −$54,462 | −27.76% |
| 2011 | 2011-12-31 | $196,183 | −$149,233 | −43.20% |
| 2010 | 2010-12-31 | $345,416 | — | — |
China Pharma Holdings quarterly stock-based compensation
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q1.14
Q3.24
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $0 | — | — |
| Q2 2025 | 2025-06-30 | $0 | — | — |
| Q3 2024 | 2024-09-30 | $0 | — | — |
| Q1 2014 | 2014-03-31 | $128,024 | −$98,466 | −43.47% |
| Q1 2013 | 2013-03-31 | $226,490 | $170,001 | +300.95% |
| Q4 2012 | 2012-12-31 | $0 | −$57,109 | — |
| Q3 2012 | 2012-09-30 | $0 | −$57,109 | — |
| Q2 2012 | 2012-06-30 | $85,232 | $45,165 | +112.72% |
| Q1 2012 | 2012-03-31 | $56,489 | $14,591 | +34.83% |
| Q4 2011 | 2011-12-31 | $57,109 | — | — |
| Q3 2011 | 2011-09-30 | $57,109 | −$3,377 | −5.58% |
| Q2 2011 | 2011-06-30 | $40,067 | — | — |
| Q1 2011 | 2011-03-31 | $41,898 | — | — |
| Q3 2010 | 2010-09-30 | $60,486 | — | — |
China Pharma Holdings stock-based compensation trends
Between the periods ended 2010-12-31 and 2023-12-31, China Pharma Holdings's stock-based compensation decreased from $345,416 to $0, a change of −$345,416. The latest reported quarter, Q2 2026, shows $0.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review China Pharma Holdings source filings ↗